top of page
Search

Guardant (GH): Start of a new product cycle

Writer: Abacus Research
Abacus Research
Sep 17, 2025
1 min read

Guardant Health is a leader in liquid biopsy, a blood test, for cancer profiling and now screening.


Guardant has two new liquid biopsy products that look to be ramping fast and are well positioned. There is a massive TAM to go after, >>$100bn vs Industry revenues of ~$3-5bn.

  • Shield, one of the new products, could be the start of a very big thing for GH, and Q2 2025 showed very encouraging momentum.


We believe that Shield could make the company: revenues could increase from $60m this year to $700m in 2028 with potential upside if Shield becomes a multi-cancer screening platform. In our opinion Guardant has a meaningful first mover advantage, it just needs to prove commercial execution.


Potential Upside: $150 (+170%) over 3 years

Sensible Downside: $23(-50%)


 
 
 

Recent Posts

See All
GOOGL, AMZN: Plays on inference and bundling

We see the power moving back towards the Hyperscalers, and find the combination of less risk, high growth and reasonable valuations to be compelling. AMZN: sensible upside to $305 (+20%) SOTP model an

 
 
 
RYAN / Insurance Cycle

Ryan (RYAN) is a typical hard market beneficiary, that is going through an organic growth reset. Are we there yet in terms of the reset- probably not. Timing the bottom of a cyclical market is hard. N

 
 
 
Nebius & DigitalOcean: Inference Efficiency

(NBIS, DOCN) 1. The Core AI Thesis At the core of all AI theses there are two beliefs: Demand for intelligence is ~infinite — this still seems to be true, at leas there is no data to the contrary. Com

 
 
 

Comments

bottom of page